AbbVie Inc (ABBV) : Northern Oak Wealth Management Inc scooped up 10,282 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 116,735 shares of AbbVie Inc which is valued at $7,297,105.AbbVie Inc makes up approximately 1.66% of Northern Oak Wealth Management Inc’s portfolio.
Other Hedge Funds, Including , Geneva Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 1,289 additional shares and now holds a total of 621,238 shares of AbbVie Inc which is valued at $38,833,587. AbbVie Inc makes up approx 0.78% of Geneva Advisors’s portfolio.Washington Trust Bank boosted its stake in ABBV in the latest quarter, The investment management firm added 3,802 additional shares and now holds a total of 51,831 shares of AbbVie Inc which is valued at $3,161,691. AbbVie Inc makes up approx 0.80% of Washington Trust Bank’s portfolio.Stratford Consulting boosted its stake in ABBV in the latest quarter, The investment management firm added 37 additional shares and now holds a total of 5,548 shares of AbbVie Inc which is valued at $340,758. AbbVie Inc makes up approx 0.16% of Stratford Consulting’s portfolio.Transamerica Financial Advisors reduced its stake in ABBV by selling 5,579 shares or 86.72% in the most recent quarter. The Hedge Fund company now holds 854 shares of ABBV which is valued at $52,453.Blb&b Advisors reduced its stake in ABBV by selling 880 shares or 1.28% in the most recent quarter. The Hedge Fund company now holds 68,081 shares of ABBV which is valued at $4,181,535. AbbVie Inc makes up approx 0.83% of Blb&b Advisors’s portfolio.
AbbVie Inc opened for trading at $63.51 and hit $63.76 on the upside on Tuesday, eventually ending the session at $63.74, with a gain of 0.06% or 0.04 points. The heightened volatility saw the trading volume jump to 1,21,03,393 shares. Company has a market cap of $103,090 M.
On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.